## David M Epstein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3484644/publications.pdf

Version: 2024-02-01

76 5,819 28 75 papers citations h-index g-index

87 87 87 87 5798

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Meeting public health objectives and supporting the resumption of tourist activity through COVID-19: a triangular perspective. Current Issues in Tourism, 2023, 26, 1617-1634.	7.2	8
2	Cost-effectiveness analysis of current varicose veins treatments. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2022, 10, 504-513.e7.	1.6	15
3	How innovation can be defined, evaluated and rewarded in health technology assessment. Health Economics Review, 2022, 12, 1.	2.0	16
4	Are costs derived from diagnosis-related groups suitable for use in economic evaluations? A comparison across nine European countries in the European Healthcare and Social Cost Database. European Journal of Health Economics, 2022, 23, 1563-1575.	2.8	3
5	Development of the European Healthcare and Social Cost Database (EU HCSCD) for use in economic evaluation of healthcare programs. BMC Health Services Research, 2022, 22, 405.	2.2	1
6	Comparing methods for handling missing cost and quality of life data in the Early Endovenous Ablation in Venous Ulceration trial. Cost Effectiveness and Resource Allocation, 2022, 20, 18.	1.5	0
7	The Stance4Health Project: Evaluating a Smart Personalised Nutrition Service for Gut Microbiota Modulation in Normal- and Overweight Adults and Children with Obesity, Gluten-Related Disorders or Allergy/Intolerance to Cow's Milk. Foods, 2022, 11, 1480.	4.3	10
8	Nutrition Economics: Celebrating Cross-Disciplinary Collaboration. Value in Health, 2021, 24, 313-316.	0.3	0
9	Consumers' Preferences and Willingness to Pay for Personalised Nutrition. Applied Health Economics and Health Policy, 2021, 19, 757-767.	2.1	6
10	Study protocol for a multicentre, randomised controlled trial to compare the use of the decellularised dermis allograft in addition to standard care versus standard care alone for the treatment of venous leg ulceration: DAVE trial. BMJ Open, 2021, 11, e041748.	1.9	1
11	Compression hosiery to avoid post-thrombotic syndrome (CHAPS) protocol for a randomised controlled trial (ISRCTN73041168). BMJ Open, 2021, 11, e044285.	1.9	4
12	Evaluation of new medicines in Spain and comparison with other European countries. Gaceta Sanitaria, 2020, 34, 133-140.	1.5	18
13	Cost-effectiveness analysis of a surveillance program to prevent hip dislocation in children with cerebral palsy. Gaceta Sanitaria, 2020, 34, 377-384.	1.5	5
14	Economic Evaluation for Pricing and Reimbursement of New Drugs in Spain: Fable or Desideratum?. Value in Health, 2020, 23, 25-31.	0.3	7
15	Long-term Clinical and Cost-effectiveness of Early Endovenous Ablation in Venous Ulceration. JAMA Surgery, 2020, 155, 1113.	4.3	25
16	A general framework for classifying costing methods for economic evaluation of health care. European Journal of Health Economics, 2020, 21, 529-542.	2.8	44
17	Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant of hematopoietic progenitor cells. Bone Marrow Transplantation, 2019, 54, 1908-1919.	2.4	7
18	Beyond the costâ€effectiveness acceptability curve: The appropriateness of rank probabilities for presenting the results of economic evaluation in multiple technology appraisal. Health Economics (United Kingdom), 2019, 28, 801-807.	1.7	8

#	Article	IF	CITATIONS
19	The price of innovation - the role of drug pricing in financing pharmaceutical innovation. A conceptual framework. Journal of Market Access & Health Policy, 2019, 7, 1583536.	1.5	13
20	Paraplegia prevention in aortic aneurysm repair by thoracoabdominal staging with â€~minimally invasive staged segmental artery coil embolisation' (MIS²ACE): trial protocol for a randomised controlled multicentre trial. BMJ Open, 2019, 9, e025488.	1.9	46
21	A multicenter randomized controlled study to evaluate whether neuromuscular electrical stimulation improves the absolute walking distance in patients with intermittent claudication compared with best available treatment. Journal of Vascular Surgery, 2019, 69, 1567-1573.	1.1	6
22	Cost-effectiveness analysis of a randomized clinical trial of early <i>versus</i> deferred endovenous ablation of superficial venous reflux in patients with venous ulceration. British Journal of Surgery, 2019, 106, 555-562.	0.3	17
23	Optimizing Surveillance and Re-intervention Strategy Following Elective Endovascular Repair of Abdominal Aortic Aneurysms. Annals of Surgery, 2019, Publish Ahead of Print, e589-e598.	4.2	1
24	Cost-effectiveness of a primary care-based exercise intervention in perimenopausal women. The FLAMENCO Project. Gaceta Sanitaria, 2019, 33, 529-535.	1.5	5
25	Early versus deferred endovenous ablation of superficial venous reflux in patients with venous ulceration: the EVRA RCT. Health Technology Assessment, 2019, 23, 1-96.	2.8	18
26	A Randomized Trial of Early Endovenous Ablation in Venous Ulceration. New England Journal of Medicine, 2018, 378, 2105-2114.	27.0	244
27	Systematic Review of the Effect of Adherence to Statin Treatment on Critical Cardiovascular Events and Mortality in Primary Prevention. Journal of Cardiovascular Pharmacology and Therapeutics, 2018, 23, 200-215.	2.0	32
28	Cost-Effectiveness of Current and Emerging Treatments of Varicose Veins. Value in Health, 2018, 21, 911-920.	0.3	36
29	Decision uncertainty and value of further research: a case-study in fenestrated endovascular aneurysm repair for complex abdominal aortic aneurysms. Cost Effectiveness and Resource Allocation, 2018, 16, 15.	1.5	3
30	Costâ€effectiveness of treatments for superficial venous reflux in patients with chronic venous ulceration. BJS Open, 2018, 2, 203-212.	1.7	8
31	The UK EndoVascular Aneurysm Repair (EVAR) randomised controlled trials: long-term follow-up and cost-effectiveness analysis. Health Technology Assessment, 2018, 22, 1-132.	2.8	89
32	Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. British Journal of Dermatology, 2017, 176, 594-603.	1.5	55
33	Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs. Health Economics (United Kingdom), 2017, 26, 109-123.	1.7	52
34	Meta-analysis of individual-patient data from EVAR-1, DREAM, OVER and ACE trials comparing outcomes of endovascular or open repair for abdominal aortic aneurysm over 5 years. British Journal of Surgery, 2017, 104, 166-178.	0.3	304
35	A Procedure for Deriving Formulas to Convert Transition Rates to Probabilities for Multistate Markov Models. Medical Decision Making, 2017, 37, 779-789.	2.4	23
36	IP273 Cost-Effectiveness of Current and Emerging Treatments of Varicose Veins. Journal of Vascular Surgery, 2017, 65, 128S.	1.1	0

#	Article	IF	CITATIONS
37	The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial. Value in Health, 2016, 19, 431-439.	0.3	20
38	Modeling the costs and long-term health benefits of screening the general population for risks of cardiovascular disease: a review of methods used in the literature. European Journal of Health Economics, 2016, 17, 1041-1053.	2.8	8
39	COST-EFFECTIVENESS OF RADIOFREQUENCY ABLATION VERSUS LASER FOR VARICOSE VEINS. International Journal of Technology Assessment in Health Care, 2015, 31, 289-296.	0.5	20
40	A comparison of the accuracy of liquid cytologyversusconventional screening: a meta-analysis of split-sample studies. Journal of the Royal Statistical Society Series A: Statistics in Society, 2014, 177, 153-168.	1.1	0
41	Cost–Utility Analysis of a Pharmacotherapy Followâ€Up for Elderly Nursing Home Residents in Spain. Journal of the American Geriatrics Society, 2014, 62, 1272-1280.	2.6	17
42	COMMENT ON â€~HETEROGENEITY IN ACTION: THE ROLE OF PASSIVE PERSONALIZATION IN COMPARATIVE EFFECTIVENESS RESEARCH'. Health Economics (United Kingdom), 2014, 23, 374-375.	1.7	0
43	A Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled Trials. Pharmacoeconomics, 2014, 32, 1157-1170.	3.3	417
44	Long-term cost-effectiveness analysis of endovascular <i>versus</i> open repair for abdominal aortic aneurysm based on four randomized clinical trials. British Journal of Surgery, 2014, 101, 623-631.	0.3	73
45	Cost-effectiveness of laparoscopic fundoplication <i>versus</i> continued medical management for the treatment of gastro-oesophageal reflux disease based on long-term follow-up of the REFLUX trial. British Journal of Surgery, 2013, 100, 1205-1213.	0.3	41
46	Cost-effectiveness of supported self-management for CFS/ME patients in primary care. BMC Family Practice, 2013, 14, 12.	2.9	14
47	Use of Multiparameter Evidence Synthesis to Assess the Appropriateness of Data and Structure in Decision Models. Medical Decision Making, 2013, 33, 715-730.	2.4	2
48	Clinical and economic evaluation of laparoscopic surgery compared with medical management for gastro-oesophageal reflux disease: 5-year follow-up of multicentre randomised trial (the REFLUX) Tj ETQq0 0 0 rg	gBT2/ <b>.®</b> verlo	ocks&0 Tf 50 2
49	Modelling the cost-effectiveness of carotid endarterectomy for asymptomatic stenosis5. British Journal of Surgery, 2012, 100, 231-239.	0.3	12
50	Golimumab for the Treatment of Psoriatic Arthritis. Pharmacoeconomics, 2012, 30, 257-270.	3.3	28
51	Invited Commentary. Journal of Vascular Surgery, 2012, 56, 910.	1.1	0
52	Análisis de coste-efectividad de la prueba de citologÃa cervicovaginal. Progresos En Obstetricia Y Ginecologia, 2012, 55, 304-311.	0.0	3
53	The UK EndoVascular Aneurysm Repair (EVAR) trials: randomised trials of EVAR versus standard therapy Health Technology Assessment, 2012, 16, 1-218.	2.8	193
54	Modelling Correlated Clinical Outcomes in Health Technology Appraisal. Value in Health, 2011, 14, 793-799.	0.3	8

#	Article	IF	CITATIONS
55	The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. European Journal of Cancer, 2011, 47, 2517-2530.	2.8	35
56	Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis. Rheumatology, 2011, 50, iv39-iv47.	1.9	24
57	Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technology Assessment, 2011, 15, i-xxi, 1-329.	2.8	84
58	Cost-effectiveness of traditional and endovenous treatments for varicose veins. British Journal of Surgery, 2010, 97, 1815-1823.	0.3	70
59	Endovascular Repair of Aortic Aneurysm in Patients Physically Ineligible for Open Repair. New England Journal of Medicine, 2010, 362, 1872-1880.	27.0	293
60	Endovascular versus Open Repair of Abdominal Aortic Aneurysm. New England Journal of Medicine, 2010, 362, 1863-1871.	27.0	1,242
61	Budgetary policies and available actions: A generalisation of decision rules for allocation and research decisions. Journal of Health Economics, 2010, 29, 170-181.	2.7	29
62	Laparoscopic fundoplication compared with medical management for gastro-oesophageal reflux disease: cost effectiveness study. BMJ: British Medical Journal, 2009, 339, b2576-b2576.	2.3	54
63	Social determinants of health: an economic perspective. Health Economics (United Kingdom), 2009, 18, 495-502.	1.7	17
64	Stapled haemorrhoidopexy for the treatment of haemorrhoids: a systematic review. Colorectal Disease, 2009, 11, 233-243.	1.4	99
65	The hospital costs of care for stroke in nine European countries. Health Economics (United Kingdom), 2008, 17, S21-S31.	1.7	46
66	Uncertainty and value of information when allocating resources within and between healthcare programmes. European Journal of Operational Research, 2008, 191, 530-539.	5.7	27
67	Economic Evaluation of Coronary Artery Bypass Grafting Surgery With and Without Cardiopulmonary Bypass: Costâ€Effectiveness and Qualityâ€Adjusted Life Years in a Randomized Controlled Trial. Artificial Organs, 2008, 32, 891-897.	1.9	25
68	Costs of an early intervention versus a conservative strategy in acute coronary syndrome. International Journal of Cardiology, 2008, 127, 240-246.	1.7	9
69	Efficiency, Equity, and Budgetary Policies. Medical Decision Making, 2007, 27, 128-137.	2.4	56
70	Randomized trial of a brief physiotherapy intervention compared with usual physiotherapy for neck pain patients: Cost-effectiveness analysis. International Journal of Technology Assessment in Health Care, 2006, 22, 67-75.	0.5	29
71	Costs and prices for inpatient care in England: Mirror twins or distant cousins?. Health Care Management Science, 2006, 9, 233-242.	2.6	27
72	Cost-Effectiveness Analysis of Treatments for Chronic Disease: Using R to Incorporate Time Dependency of Treatment Response. Medical Decision Making, 2005, 25, 511-519.	2.4	32

#	Article	IF	CITATIONS
73	Assessing the Cost-Effectiveness of New Pharmaceuticals in Epilepsy in Adults: The Results of a Probabilistic Decision Model. Medical Decision Making, 2005, 25, 493-510.	2.4	25
74	Endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR) Tj ETQq0 C	0 rgBT /C	Overlock 10 Tf !
75	Intensive rehabilitation may be more cost effective than surgical stabilisation for chronic low back pain. Australian Journal of Physiotherapy, 2005, 51, 269.	0.9	1
76	The UK Endovascular Aneurysm Repair (EVAR) Trials: Design, Methodology and Progress. European Journal of Vascular and Endovascular Surgery, 2004, 27, 372-381.	1.5	125